8-K: Sensus Healthcare Reports Record SRT System Shipments and Fifth Consecutive Quarter of Profitability in Q4 2024

Sensus Healthcare announces strong Q4 and full-year 2024 financial results, highlighted by record SRT system shipments and continued profitability.

Summary

• Sensus Healthcare reported its Q4 and full-year 2024 financial results on February 5, 2025.
• Q4 revenues reached $13.1 million, a 4% increase compared to Q4 2023.
• Full-year revenues were $41.8 million, a significant 71% increase year-over-year.
• The company achieved a net income of $1.5 million in Q4, resulting in diluted EPS of $0.09, marking the fifth consecutive profitable quarter.
• A record 39 SRT systems were shipped in Q4, and 115 systems were shipped throughout the year, representing increases of 18% and 74% respectively.
• International shipments included five systems in Q4 and ten systems for the full year.
• Sensus Healthcare ended the year with $22.1 million in cash and cash equivalents and no debt.
• The company anticipates first quarter 2025 sales could be considerably lower than first quarter 2024 sales, with full-year sales growth in 2025 versus 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth and continued profitability, but tempered by the expected lower sales in Q1 2025 and increased expenses.

Positives

• Sensus Healthcare achieved a 71% increase in full-year revenues, reaching $41.8 million.
• The company shipped a record 115 SRT systems throughout the year, a 74% increase compared to the previous year.
• Sensus Healthcare reported its fifth consecutive quarter of profitability, with a net income of $1.5 million in Q4.
• The company ended the year with a strong cash position of $22.1 million and no debt.
• The company is expanding its reach internationally, shipping systems to new and existing markets.

Negatives

• Gross profit for the fourth quarter of 2024 decreased to $7.1 million, or 54.4% of revenues, compared with $7.8 million, or 62.3% of revenues, for the fourth quarter of 2023, primarily due to a one-time discount to a new large group customer and higher cost of service.
• Adjusted EBITDA for the fourth quarter of 2024 was $1.9 million, compared with $5.7 million for the fourth quarter of 2023.
• The company anticipates first quarter 2025 sales could be considerably lower than first quarter 2024 sales.

Risks

• The company acknowledges that inflationary pressures could impact sales.
• The level of government and third-party payor reimbursement for procedures using their products could affect sales.
• The company's customer base is concentrated in the U.S. and China, posing a risk if those markets weaken.
• Competition from new products or technologies could render Sensus Healthcare's technology obsolete.
• The company faces risks associated with doing business in China and other foreign countries.

Future Outlook

The company expects first quarter 2025 sales could be considerably lower than first quarter 2024 sales, with full-year sales growth in 2025 versus 2024. The company plans to re-submit its TDI 510(k) application in the first half of 2025.

Management Comments

• Joe Sardano, Chairman and CEO, stated that the fourth quarter performance capped an outstanding year with key metrics reflecting the growing adoption of their SRT systems.
• He highlighted the success of the Fair Deal Agreement program and its expected contribution to revenues in the second half of 2025.
• He also mentioned strategic progress on product innovation and plans to re-submit the TDI 510(k) application in the first half of 2025.

Industry Context

Sensus Healthcare operates in the medical device industry, specifically focusing on non-invasive treatments for skin cancer and keloids. The company's performance reflects the growing adoption of superficial radiotherapy (SRT) systems in dermatology and radiation oncology. The company is also expanding into the veterinary market, demonstrating the versatility of its technology.

Comparison to Industry Standards

• Comparing Sensus Healthcare to companies like Accuray Incorporated (ARAY) and Elekta AB, which operate in the broader radiation oncology market, Sensus distinguishes itself with its focus on superficial radiotherapy for skin conditions.
• While Accuray and Elekta offer more comprehensive radiation therapy solutions, Sensus Healthcare's SRT systems provide a niche offering for non-invasive skin treatments.
• The company's growth in SRT system shipments and revenue indicates a strong market demand for its specialized technology.
• The company's focus on Fair Deal Agreements is similar to leasing programs offered by other medical device companies to reduce upfront costs for customers.

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and profitability.
• Healthcare providers gain access to effective non-invasive treatment solutions.
• Patients benefit from safe and precise treatment options for skin cancer and keloids.

Next Steps

• The company plans to attend the 2025 American Academy of Dermatology Annual Meeting in March.
• Sensus Healthcare plans to re-submit its TDI 510(k) application in the first half of 2025.
• The company will focus on expanding patient access through Fair Deal Agreements and strengthening customer relationships.

Key Dates

Keywords

Sensus Healthcare, SRT systems, Financial Results, Superficial Radiotherapy, Revenues, Net Income, EBITDA, Medical Device, Oncology, Dermatology